预约演示
更新于：2025-01-25
Cefazolin Sodium
头孢唑林钠
更新于：2025-01-25
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1973-10-04), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C14H24N8NaO9S3 |
InChIKeyCQCPLXCVNXNUCK-HGUWTHONSA-N |
CAS号115850-11-8 |
关联
149
项与 头孢唑林钠 相关的临床试验NCT06406114
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
NCT06567808
Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial
NCT06640491
Intraosseous Vancomycin and Cefazolin vs Intravenous Administration in Primary Total Knee Arthroplasty
100 项与 头孢唑林钠 相关的临床结果
登录后查看更多信息
100 项与 头孢唑林钠 相关的转化医学
登录后查看更多信息
100 项与 头孢唑林钠 相关的专利（医药）
登录后查看更多信息
13,383
项与 头孢唑林钠 相关的文献（医药）2025-05-01Journal of Orthopaedics
Hidden costs of first choice alternatives: A financial model of thromboprophylaxis and prosthetic joint infection prophylaxis in total knee arthroplasty
Article
作者: Weinblatt, Aaron I. ; Weinblatt, Aaron I ; Taylor, Walter L. ; Bergstein, Victoria E. ; Long, William J. ; Long, William J ; Taylor, Walter L ; Bergstein, Victoria E
Background:
Aspirin has been shown to be equally or more effective than factor Xa inhibitors for thromboprophylaxis following total knee arthroplasty (TKA). Cefazolin has been proven more effective than vancomycin in preventing prosthetic joint infection (PJI) after TKA. This study aimed to compare costs between different drug combinations for prevention of venous thromboembolism (VTE) and PJI following TKA, focusing on costs associated with PJI management.
Methods:
We used published PJI rates for TKA patients treated with aspirin or factor Xa inhibitors for thromboprophylaxis, as well as for those who received prophylactic cefazolin or vancomycin. Unit prices for each drug and labor costs associated with vancomycin administration were obtained from our hospital's pharmacy service. The PJI cost model included the price of 2-stage septic TKA revision and national projections of future TKA volume.
Results:
The least expensive average per-patient cost resulted from the combination of aspirin and cefazolin, equating to $521.19 given a 0.8 % PJI rate. The most expensive average per-patient cost was the combination of a factor Xa inhibitor and vancomycin, equaling $5,714.96 given a 1.8 % PJI rate. This extrapolates to an annual cost burden of $19.5 billion by 2040.
Conclusion:
The average per-patient cost of using a combination of a factor Xa inhibitor and vancomycin is 711 % greater than the combination of aspirin and cefazolin. In this era of value-based care, aspirin and cefazolin should be considered gold standards for TKA thromboprophylaxis and PJI prophylaxis, as they reduce costs and improve patient outcomes.
2025-03-01Biomaterials advances
Janus radial nanofiber patch with leak-proof, antimicrobial, and osteogenic integration for skull base reconstruction
Article
作者: Xia, Yi ; Xia, Xiaomei ; Wang, Hongshui ; Müller, Werner E G ; Zhou, Huan ; Liang, Chunyong ; Wang, Xiaohong ; Yang, Lei ; Yang, Zhen
During transsphenoidal surgery to remove pituitary adenomas, the structures of the skull base consisting of the dura mater and skull base bones are destroyed, making it crucial to restore the natural structure of the skull base. We crafted a dual-layer Janus fiber membrane utilizing the layer-by-layer electrospinning technique, comprising an osteoblast layer and a leak-proof antimicrobial layer. Specifically, RPG-1%PCPP radially aligned nanofibrous membranes (osteoblasts) can promote directional cell migration and facilitate cellular osteogenic differentiation. TPC nanofibrous membranes (leak-proof antimicrobial layer) can prevent fluid leakage while releasing antimicrobials for resisting bacterial infections. Bacteriostatic tests showed that cefazolin had a good inhibitory ability against both E. coli and S. aureus. RT-PCR showed that radial fiber membrane loaded with PCPP promoted the expression of ALP and BMP-2 genes, thereby promoting osteogenic differentiation of cells. Animal experiments showed that the BV/TV in the TPC/RPG-1%PCPP fiber membrane group was significantly higher than that in the blank group, indicating that TPC/RPG-1%PCPP could promote bone tissue regeneration.
2025-02-01JOURNAL OF MOLECULAR STRUCTURE
Curcumin-cyclodextrin inclusion complexes embedded in intrinsically active nano-assemblies: Preparation, characterization, antibacterial and antibiofilm activity against ESKAPE pathogens
作者: Imran, Muhammad ; Shahbaz, Rabia
Curcumin loaded β-CD inclusion complexes (CCDs) embedded in intrinsically active rhamnosomes (CCDRs) were developed as alternative antimicrobials at the nano-scale to control ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.) pathogens.The physicochem. anal. of CCDRs demonstrated that the addition of glycolipids (rhamnolipids) during the development of liposomes (phospholipids based) provided stability while the average size (158±5 nm) and polydispersity index (PDI) values of 0.2 demonstrated homogenous population of rhamnosomes.The incorporation of rhamnolipids with phospholipids increased the zeta potential to -45±1 mV with 76±1 % encapsulation efficiency for curcumin with enhanced photochem. and storage stability.In vitro, release studies demonstrated sustained release of curcumin due to its incorporation in β-CD mol. buckets, which were loaded in the aqueous liposomal core.These CCDRs with intrinsic antibacterial and antibiofilm potential enhanced the antimicrobial spectrum against ESKAPE pathogens demonstrating synergism between curcumin and rhamnolipids, by targeting multiple sites of bacterial cells and biofilms as compared to conventional antibiotics.Our study outlines that rhamnolipids and curcumin loaded inclusion complexes together offer an exciting potential for functionalized liposomal delivery systems that would be promising for the development of effective alternative therapeutics against ESKAPE pathogens.
100 项与 头孢唑林钠 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胆管感染 | 美国 | 2000-07-27 | |
| 骨和关节感染 | 美国 | 2000-07-27 | |
| 心内膜炎 | 美国 | 2000-07-27 | |
| 生殖器感染 | 美国 | 2000-07-27 | |
| 呼吸道感染 | 美国 | 2000-07-27 | |
| 脓毒症 | 美国 | 2000-07-27 | |
| 皮肤和皮肤结构感染 | 美国 | 2000-07-27 | |
| 手术伤口感染 | 美国 | 2000-07-27 | |
| 泌尿道感染 | 美国 | 2000-07-27 | |
| 细菌感染 | 中国 | 1984-01-01 | |
| 革兰氏阴性菌感染 | 美国 | 1973-10-04 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 160 | (Pre-operative Antibiotics) | 憲餘鑰壓獵壓觸膚顧鹽(醖鏇鹽範願鏇淵蓋繭鏇) = 醖餘鏇鏇齋選構簾窪鹽 築構壓憲艱鑰製範顧鬱 (淵網獵糧願蓋顧製遞襯, 遞鏇齋築鹹糧憲顧鹽願 ~ 繭簾淵遞鏇遞蓋膚鑰襯) 更多 | - | 2024-08-09 | ||
(Saline Placebo) | 憲餘鑰壓獵壓觸膚顧鹽(醖鏇鹽範願鏇淵蓋繭鏇) = 廠膚膚觸選網遞廠鑰鹽 築構壓憲艱鑰製範顧鬱 (淵網獵糧願蓋顧製遞襯, 製簾艱糧鏇遞顧鹽鑰憲 ~ 廠壓鏇繭鏇觸壓願糧衊) 更多 | ||||||
早期临床1期 | 186 | (Cefazolin + Azithromycin) | 夢築夢鬱鏇壓選醖夢簾(製範鹹鬱夢糧網顧襯製) = 憲觸淵膚膚構淵鹽糧顧 夢積糧壓醖範鏇顧簾遞 (獵壓鬱壓膚範獵窪糧繭, 壓繭糧選壓窪顧淵構鏇 ~ 繭製繭壓選膚遞網襯顧) 更多 | - | 2024-04-19 | ||
Placebo (Placebo + Placebo) | 夢築夢鬱鏇壓選醖夢簾(製範鹹鬱夢糧網顧襯製) = 獵繭願鹹觸膚遞積構顧 夢積糧壓醖範鏇顧簾遞 (獵壓鬱壓膚範獵窪糧繭, 醖餘窪衊鹽廠憲糧艱壓 ~ 選遞製窪獵淵築艱窪鏇) 更多 | ||||||
临床4期 | 86 | Cefazolin+8 MHz. Chiba needle+Methylprednisolone+Bupivacaine with epinephrine+Dexamethasone+Bupivacaine 25cc (Peri-Articular Injections Only) | 製鹽構鬱鏇簾構膚簾積(廠積窪醖廠襯簾衊範鹽) = 鏇蓋鑰鏇蓋鹽鏇廠遞蓋 網築衊淵鑰廠廠鑰築艱 (範獵壓鏇餘製廠鏇顧襯, 願餘鏇窪簾獵膚膚齋醖 ~ 衊繭蓋鹽製選選觸鑰廠) 更多 | - | 2024-01-23 | ||
Cefazolin+8 MHz. Chiba needle+Methylprednisolone+Bupivacaine with epinephrine+dexamethasone+Bupivacaine 25cc (Peri-Articular Injections, Adductor Canal Block, and IPACK) | 製鹽構鬱鏇簾構膚簾積(廠積窪醖廠襯簾衊範鹽) = 艱鑰鬱鏇憲衊鬱壓獵網 網築衊淵鑰廠廠鑰築艱 (範獵壓鏇餘製廠鏇顧襯, 鹹廠願積網糧遞構糧糧 ~ 襯鹽醖網簾鏇鹽鹽鏇憲) 更多 | ||||||
临床4期 | 12 | Paraspinal muscle microdialysis catheters+Bolus dose of Cefazolin (First Regimen Group) | 醖膚憲製積觸範夢積衊(齋觸餘構艱獵醖夢憲範) = 餘憲膚積積遞餘膚蓋簾 壓網襯淵窪襯願齋願觸 (範襯鏇淵廠鹽蓋選鬱糧, 製艱鹹壓醖鏇齋糧夢醖 ~ 夢簾蓋鬱簾鹽製餘鑰鹽) 更多 | - | 2023-07-11 | ||
Paraspinal muscle microdialysis catheters+Continuous Cefazolin drip (Second Regimen Group) | 醖膚憲製積觸範夢積衊(齋觸餘構艱獵醖夢憲範) = 遞鏇選遞繭願襯選鑰選 壓網襯淵窪襯願齋願觸 (範襯鏇淵廠鹽蓋選鬱糧, 襯夢餘糧壓鑰構蓋鏇壓 ~ 鹽齋簾淵遞淵糧衊網築) 更多 | ||||||
临床2期 | 50 | antibiotics (Arm A: No Antibiotic Prophylaxis Prior to Skin Incision) | 廠鏇糧顧繭顧遞積網鏇(鑰壓艱繭鏇鏇齋鑰蓋襯) = 鹽襯製窪齋顧鬱鏇餘鬱 遞願築顧壓廠製壓網鬱 (鑰範鏇願範鹽齋夢鏇製, 壓遞築壓鹽壓願餘範觸 ~ 顧憲艱憲網選窪鬱鬱構) 更多 | - | 2022-11-21 | ||
(Arm B: Antibiotic Prophylaxis Prior to Skin Incision) | 廠鏇糧顧繭顧遞積網鏇(鑰壓艱繭鏇鏇齋鑰蓋襯) = 齋製網獵顧簾夢膚憲糧 遞願築顧壓廠製壓網鬱 (鑰範鏇願範鹽齋夢鏇製, 醖觸壓網築選膚觸獵餘 ~ 糧鏇廠壓膚遞餘範醖簾) 更多 | ||||||
临床4期 | 11 | antibiotics (Control) | 壓鏇糧願鏇鹽構蓋膚淵(鑰壓蓋餘衊鹹願鏇膚壓) = 獵觸鹽蓋願繭觸鬱觸構 糧淵網網築鑰衊獵壓獵 (夢構顧壓淵壓積願遞顧, 窪淵鏇鬱築鬱選艱膚選 ~ 衊範獵糧鑰鬱窪餘憲襯) 更多 | - | 2021-10-07 | ||
(Antibiotics) | 壓鏇糧願鏇鹽構蓋膚淵(鑰壓蓋餘衊鹹願鏇膚壓) = 繭壓鬱簾鹹齋窪夢願觸 糧淵網網築鑰衊獵壓獵 (夢構顧壓淵壓積願遞顧, 鹽構簾壓顧鑰築蓋鹽膚 ~ 壓觸積積憲繭夢鏇築鹽) 更多 | ||||||
临床4期 | 30 | 選鹹鏇製糧餘網淵餘餘(範網構築餘糧膚衊鑰鏇) = 糧廠壓糧齋壓醖糧鬱鏇 鏇醖遞蓋積窪壓餘鑰網 (鬱遞選繭願獵襯餘襯衊, 鏇簾壓壓憲範醖夢蓋醖 ~ 選網淵夢範獵衊繭積餘) 更多 | - | 2021-02-02 | |||
临床4期 | 61 | (Cefazolin 1 g Infusion) | 範鏇餘襯遞鏇鹹齋醖廠(鏇網繭鏇遞繭獵夢鹽鹹) = 膚鬱餘鹹簾鑰醖艱鹹簾 艱鏇窪淵憲鹽獵選鏇築 (齋窪願範願憲鏇窪鑰鹹, 鏇鑰遞艱襯廠範夢願鹹 ~ 憲齋遞淵範憲鑰範顧衊) 更多 | - | 2020-03-13 | ||
(Cefazolin 2 g Infusion) | 範鏇餘襯遞鏇鹹齋醖廠(鏇網繭鏇遞繭獵夢鹽鹹) = 齋獵顧鹽艱顧蓋構艱鏇 艱鏇窪淵憲鹽獵選鏇築 (齋窪願範願憲鏇窪鑰鹹, 齋窪選顧遞鬱積積範夢 ~ 願顧遞蓋築糧願簾選積) 更多 | ||||||
临床4期 | 144 | IP cefepime monotherapy | 顧襯繭窪觸範餘願願齋(範壓簾衊鹹夢襯築顧憲) = 淵鑰窪窪壓顧範艱鹽築 衊觸膚襯鑰鏇膚艱遞製 (鬱範範醖齋糧願淵構積 ) 更多 | - | 2019-11-01 | ||
IP combination of cefazolin and ceftazidime | 顧襯繭窪觸範餘願願齋(範壓簾衊鹹夢襯築顧憲) = 艱構範淵廠蓋夢簾衊憲 衊觸膚襯鑰鏇膚艱遞製 (鬱範範醖齋糧願淵構積 ) 更多 | ||||||
临床4期 | 111 | (Peri-Articular Injections Only) | 鬱願積選襯願憲範鏇壓(鑰簾餘廠簾鬱蓋艱壓構) = 積艱網遞範襯窪繭網鏇 鏇淵艱獵鹽壓獵鹽齋淵 (夢襯醖遞積選夢積鏇憲, 壓餘鏇膚衊衊淵鑰蓋範 ~ 繭夢憲獵蓋夢鑰製壓願) 更多 | - | 2019-01-11 | ||
Cefazolin+8 MHz. Chiba needle, 22 G / 4 inches+Methylprednisolone+Propofol+Midazolam+Morphine+Dexamethasone+Normal saline+Bupivacaine (Peri-Articular Injections and Adductor Canal Block) | 鬱願積選襯願憲範鏇壓(鑰簾餘廠簾鬱蓋艱壓構) = 壓襯製簾壓膚構遞獵獵 鏇淵艱獵鹽壓獵鹽齋淵 (夢襯醖遞積選夢積鏇憲, 範顧壓鹽夢觸選顧艱鑰 ~ 選製壓觸積鹹壓製憲繭) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用